These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34301329)

  • 1. Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada.
    Iaboni A; Kanani A; Lacuesta G; Song C; Kan M; Betschel SD
    Allergy Asthma Clin Immunol; 2021 Jul; 17(1):78. PubMed ID: 34301329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.
    Riedl MA; Bernstein JA; Craig T; Banerji A; Magerl M; Cicardi M; Longhurst HJ; Shennak MM; Yang WH; Schranz J; Baptista J; Busse PJ
    Clin Transl Allergy; 2017; 7():36. PubMed ID: 29043014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of lanadelumab on attack frequency and QoL in Japanese patients with hereditary angioedema: Report of five cases.
    Hioki C; Oda Y; Moriwaki S; Fukunaga A
    J Dermatol; 2024 Jun; 51(6):873-877. PubMed ID: 38268496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lanadelumab: A Review in Hereditary Angioedema.
    Syed YY
    Drugs; 2019 Nov; 79(16):1777-1784. PubMed ID: 31560114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience.
    Abuzakouk M; Ghorab O; Al-Hameli H; Salvo F; Grandon D; Maurer M
    World Allergy Organ J; 2022 Jul; 15(7):100664. PubMed ID: 35891672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
    Banerji A; Bernstein JA; Johnston DT; Lumry WR; Magerl M; Maurer M; Martinez-Saguer I; Zanichelli A; Hao J; Inhaber N; Yu M; Riedl MA;
    Allergy; 2022 Mar; 77(3):979-990. PubMed ID: 34287942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab.
    Wong JCY; Chiang V; Lam DLY; Lee E; Lam K; Au EYL; Li PH
    J Allergy Clin Immunol Glob; 2023 Nov; 2(4):100166. PubMed ID: 38024849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lanadelumab to treat hereditary angioedema.
    Wedi B
    Drugs Today (Barc); 2019 Jul; 55(7):439-448. PubMed ID: 31347612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Use of Lanadelumab in an Older Patient With Type II Hereditary Angioedema.
    Hellu MT; Weiss MS; Smith D
    Fed Pract; 2022 Sep; 39(9):390-392. PubMed ID: 36583088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study.
    Hide M; Ohsawa I; Nurse C; Yu M;
    J Dermatol; 2023 Nov; 50(11):1381-1391. PubMed ID: 37574953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Analysis in Patients With HAE Under Prophylaxis With Lanadelumab: A Real-life Experience.
    Hahn J; Trainotti S; Wigand MC; Schuler PJ; Hoffmann TK; Greve J
    J Drugs Dermatol; 2020 Oct; 19(10):978-983. PubMed ID: 33026762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.
    Riedl MA; Maurer M; Bernstein JA; Banerji A; Longhurst HJ; Li HH; Lu P; Hao J; Juethner S; Lumry WR;
    Allergy; 2020 Nov; 75(11):2879-2887. PubMed ID: 32452549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
    Banerji A; Riedl MA; Bernstein JA; Cicardi M; Longhurst HJ; Zuraw BL; Busse PJ; Anderson J; Magerl M; Martinez-Saguer I; Davis-Lorton M; Zanichelli A; Li HH; Craig T; Jacobs J; Johnston DT; Shapiro R; Yang WH; Lumry WR; Manning ME; Schwartz LB; Shennak M; Soteres D; Zaragoza-Urdaz RH; Gierer S; Smith AM; Tachdjian R; Wedner HJ; Hebert J; Rehman SM; Staubach P; Schranz J; Baptista J; Nothaft W; Maurer M;
    JAMA; 2018 Nov; 320(20):2108-2121. PubMed ID: 30480729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema.
    Anderson J; Maina N
    Clin Transl Allergy; 2022 Jan; 12(1):e12092. PubMed ID: 35079346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France.
    Fain O; Du-Thanh A; Gobert D; Launay D; Inhaber N; Boudjemia K; Aubineau M; Sobel A; Boccon-Gibod I; Weiss L; Bouillet L
    Allergy Asthma Clin Immunol; 2022 Apr; 18(1):30. PubMed ID: 35365234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
    Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B
    N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights.
    Petkova E; Yordanova V; Staevska M; Valerieva A
    Drug Healthc Patient Saf; 2022; 14():195-210. PubMed ID: 36578774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world changes in costs over time among patients in the United States with hereditary angioedema on long-term prophylaxis with lanadelumab.
    Shah CH; Princic N; Evans KA; Schultz BG
    J Med Econ; 2023; 26(1):871-877. PubMed ID: 37395381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lanadelumab for the prevention of attacks in hereditary angioedema.
    Valerieva A; Senter R; Wu MA; Zanichelli A; Cicardi M
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1239-1248. PubMed ID: 31721602
    [No Abstract]   [Full Text] [Related]  

  • 20. Lanadelumab for the treatment of hereditary angioedema.
    Wu MA
    Expert Opin Biol Ther; 2019 Dec; 19(12):1233-1245. PubMed ID: 31657963
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.